Publications by authors named "Steve Schey"

Claim this Profile
I
Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics.
Hugh Kikuchi, Eunice Amofa, Maeve Mcenery, Steve Arthur Schey, Karthik Ramasamy

Cancers (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
Rakesh Popat, Nicholas Counsell, Ruth de Tute, Dunnya De-Silva, Elizabeth H Phillips, Steve Schey

Br J Haematol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.
David C Fajgenbaum, David Wu, Aaron Goodman, Raymond Wong, Amy Chadburn, Steve Schey

Am J Hematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Paul G Richardson, Albert Oriol, Meral Beksac, Anna Marina Liberati, Monica Galli, Steve Schey

Lancet Oncol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of relapse of multiple myeloma following kidney transplantation.
Sapna Shah, Maria Ibrahim, Michael Delaney, Steve Schey, Ceri Bygrave

Clin Kidney J· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is the revised International staging system for myeloma valid in a real world population?
Ieuan Walker, Alice Coady, Michael Neat, Darius Ladon, Reuben Benjamin, Steve Schey

Br J Haematol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods.
Christina Ramsenthaler, Wei Gao, Richard J Siegert, Steve A Schey, Poly M Edmonds

Qual Life Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma.
Joanna M Davies, Thomas R Osborne, Polly M Edmonds, Steve A Schey, Steve Devereux

Eur J Haematol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
Nicola Maciocia, Andrew Melville, Simon Cheesman, Faye Sharpley, Karthik Ramasamy, Steve Schey

Br J Haematol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5.
Steve Schey, Luis Felipe Casado Montero, Chloe Stengel-Tosetti, Craig J Gibson, Sujith Dhanasiri

Oncol Ther· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.
Christopher Parrish, Curly T C M Morris, Cathy D Williams, David A Cairns, Jamie Cavenagh, Steve Schey

Biol Blood Marrow Transplant· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
Steve Schey, Sarah R Brown, Avie-Lee Tillotson, Kwee Yong, Cathy Williams

Br J Haematol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales.
Ruth E Brown, Sean Stern, Sujith Dhanasiri, Steve Schey

Eur J Health Econ· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma.
Sally Moore, Sangeeta Atwal, Sajitha Sachchithanantham, Matthew Streetly, Iftekhar Khan, Steve Schey

Eur J Haematol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
Niels W C J van de Donk, Henk M Lokhorst, Meletios Dimopoulos, Michele Cavo, Gareth Morgan, Steve Schey

Cancer Treat Rev· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of lenalidomide in multiple myeloma.
Steve Schey, Irene Higginson

Expert Rev Pharmacoecon Outcomes Res· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death.
Matthew J Streetly, Lenushka Maharaj, Simon Joel, Steve A Schey, John G Gribben

Blood· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England.
Karen J Phekoo, Mike A Richards, Henrik Møller, Steve A Schey,

Haematologica· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Life-threatening motor neurotoxicity in association with bortezomib.
Sunil Gupta, Antonio Pagliuca, Steve Devereux, Ghulam J Mufti, Steve Schey

Haematologica· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic value of interim positron emission tomography scans combined with immunohistochemical data in diffuse large B-cell lymphoma.
Paul A Fields, George Mikhaeel, Martin Hutchings, Jon van der Walt, Tom Nunan, Steve A Schey

Haematologica· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Future directions in multiple myeloma treatment.
J Anthony Child, Nigel Russell, Pieter Sonneveld, Steve Schey

Acta Haematol· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis.
Matthew Streetly, Beverley J Hunt, Kiran Parmar, Richard Jones, Jerome Zeldis, Steve Schey

Eur J Haematol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.
Emma Morris, Kirsty Thomson, Charles Craddock, Prem Mahendra, Donald Milligan, Steve Schey

Blood· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of a specialist haematological malignancy database against a regional cancer registry: case ascertainment and diagnostic accuracy.
Karen Phekoo, Henrik Møller, Mike Richards, Steve Schey

Br J Haematol· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis